Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Topics : Diseases and conditions
  • Active substance : omalizumab
Filter
Topic
  • Diagnostic and therapeutic techniques (2)
  • Plus ...
    • Drug therapy (1)
    • Interventional imaging (1)
  • Diseases and conditions (2)
  • Plus ...
    • Respiratory tract diseases (2)
    • Plus ...
      • Pulmonary and pleural diseases (2)
      • Bronchial diseases (2)
    • Skin and connective tissue diseases (1)
    • Immune system diseases (1)
    • Plus ...
      • Allergy (1)
  • Economics and public health (1)
  • Plus ...
    • Health economics (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Drugs, devices and medical acts (2)
  • Plus ...
    • Medicine (1)
    • Health technology assessment (1)
Date
  • Last five years (1)
Language
  • Français (2)
Active substance
  • acide clavulanique (1)
  • aminophylline (1)
  • amoxicilline (1)
  • aspirine (1)
  • atropine (1)
  • clindamycine (1)
  • fentanyl (1)
  • midazolam (1)
  • omalizumab (2)
  • prednisone (1)
  • propofol (1)
  • salbutamol (1)
 More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 2 results

  • XOLAIR

    Medicine - Posted on 18/9/2024
    Add to my selection

  • Assessment of bronchial thermoplasty for the treatment of uncontrolled severe asthma - INAHTA Brief

    Health technology assessment - Posted on 28/1/2016
    Download document
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
a3vF8xGnYddtYAg3